First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Latest Information Update: 30 Dec 2024
At a glance
- Drugs STX-721 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Scorpion Therapeutics
- 31 Oct 2023 Planned End Date changed from 1 May 2028 to 1 Jun 2028.
- 31 Oct 2023 Planned primary completion date changed from 17 Jul 2026 to 1 Jun 2027.
- 10 Oct 2023 According to Scorpion Therapeutics media release, status changed from not yet recruiting to recruiting.